Cargando…

Clinical Significance of Novel Neutrophil-Based Biomarkers in the Diagnosis and Prediction of Response to Infliximab Therapy in Crohn’s Disease

With the increasing incidence and prevalence, Crohn’s disease (CD) has become one of the most challenging diseases in both diagnosis and treatment of gastroenterology. Evaluation of the disease activity and mucosal healing guides clinical decisions regarding subsequent therapy for CD. In this study,...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zhou, Zhou, Zhang, Yinghui, Yang, Xue, Pan, Yan, Li, Liangping, Gao, Caiping, He, Chong
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2022
Materias:	Immunology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8931310/ https://www.ncbi.nlm.nih.gov/pubmed/35309310 http://dx.doi.org/10.3389/fimmu.2022.865968

Ejemplares similares

A Novel Neutrophil-Based Biomarker to Monitor Disease Activity and Predict Response to Infliximab Therapy in Patients With Ulcerative Colitis
por: Zhou, Zhou, et al.
Publicado: (2022)

A Novel Model Based on Serum Biomarkers to Predict Primary Non-Response to Infliximab in Crohn’s Disease
por: Li, Li, et al.
Publicado: (2021)

Characterization of Two TNF-Related Subtypes Predicting Infliximab Therapy Responses in Crohn’s Disease
por: Ye, Chenglin, et al.
Publicado: (2022)

Infliximab trough levels are associated with endoscopic healing but not with transmural healing at one year treatment with infliximab in pediatric patients with Crohn’s disease
por: Choi, So Yoon, et al.
Publicado: (2023)

Clinical Utility of the Neutrophil-to-Bilirubin Ratio in the Detection of Disease Activity in Ulcerative Colitis
por: Huang, Xijing, et al.
Publicado: (2023)

Clinical significance of the C-reactive protein-to-bilirubin ratio in patients with ulcerative colitis
por: Huang, Xijing, et al.
Publicado: (2023)

Anti-NMDAR encephalitis in Crohn’s disease undergoing long-term infliximab treatment: A case report
por: Oh, Shin Ju, et al.
Publicado: (2022)

Formyl Peptide Receptors and Annexin A1: Complementary Mechanisms to Infliximab in Murine Experimental Colitis and Crohn’s Disease
por: de Paula-Silva, Marina, et al.
Publicado: (2021)

Infliximab in the treatment of Crohn’s disease
por: Poggioli, Gilberto, et al.
Publicado: (2007)

Infliximab trough level combined with inflammatory biomarkers predict long-term endoscopic outcomes in Crohn’s disease under infliximab therapy
por: Cao, Wan-Ting, et al.
Publicado: (2022)

Multi-alleles predict primary non-response to infliximab therapy in Crohn’s disease
por: Zhang, Cai-Bin, et al.
Publicado: (2020)

Infliximab to treat Crohn’s disease: an update
por: Cottone, M, et al.
Publicado: (2011)

The relationship between infliximab concentrations, antibodies to infliximab and disease activity in Crohn's disease
por: Vande Casteele, Niels, et al.
Publicado: (2015)

Serum Levels of Infliximab and Anti-Infliximab Antibodies in Brazilian Patients with Crohn's Disease
por: Gomes, Luis Eduardo Miani, et al.
Publicado: (2019)

Cytokine Profile at Diagnosis Affecting Trough Concentration of Infliximab in Pediatric Crohn’s Disease
por: Kwon, Yiyoung, et al.
Publicado: (2022)

Derlin-1, as a Potential Early Predictive Biomarker for Nonresponse to Infliximab Treatment in Rheumatoid Arthritis, Is Related to Autophagy
por: Cai, Yongsong, et al.
Publicado: (2022)

A Novel Radiomics Nomogram for the Prediction of Secondary Loss of Response to Infliximab in Crohn’s Disease
por: Chen, Yueying, et al.
Publicado: (2021)

A novel role of prognostic nutritional index in predicting the effectiveness of infliximab in Crohn's disease
por: Peng, Ziheng, et al.
Publicado: (2023)

Profile of infliximab in the treatment of pediatric Crohn’s disease
por: Kierkus, Jaroslaw, et al.
Publicado: (2015)

Metastatic Crohn’s disease despite infliximab therapy
por: Campos, Sara, et al.
Publicado: (2017)

Myelolipoma After Infliximab Treatment for Crohn's Disease
por: Cesa, Kevin, et al.
Publicado: (2022)

Infliximab for medical induction of remission in Crohn's disease
por: Gordon, Morris, et al.
Publicado: (2023)

Optimized timing of using infliximab in perianal fistulizing Crohn's disease
por: Sun, Xue-Liang, et al.
Publicado: (2020)

A novel role of the splenic volume in Crohn’s disease: evaluating the efficacy of infliximab
por: Shi, Xuan, et al.
Publicado: (2023)

Clinical correlations of infliximab trough levels and antibodies to infliximab in South Korean patients with Crohn’s disease
por: Oh, Eun Hye, et al.
Publicado: (2017)

Infliximab therapy in pediatric Crohn’s disease: a review
por: Parashette, Kalyan Ray, et al.
Publicado: (2010)

Maintenance treatment with infliximab for the management of Crohn’s disease in adults
por: Caviglia, Renato, et al.
Publicado: (2009)

Infliximab-induced intertriginous psoriasis in patient with Crohn's disease
por: Mola, Federica, et al.
Publicado: (2011)

Refractory Duodenal Crohn's Disease Successfully Treated with Infliximab
por: Kim, You Lim, et al.
Publicado: (2014)

Infliximab in the Treatment of Crohn Disease and Type 1 Diabetes
por: Timper, Katharina, et al.
Publicado: (2013)

Efficacy of Infliximab for the Treatment of Oral Manifestation of Crohn’s Disease
por: Aginbay, Aibar, et al.
Publicado: (2022)

Altered calcium influx of peripheral Th2 cells in pediatric Crohn's disease: infliximab may normalize activation patterns
por: Orbán, Csaba, et al.
Publicado: (2016)

Infliximab treatment of glycogenosis Ib with Crohn's-like enterocolitis: A case report
por: Gong, You-Zhe, et al.
Publicado: (2021)

Adrenomedullin: A Novel Therapy for Intractable Crohn's Disease with a Loss of Response to Infliximab
por: Ashizuka, Shinya, et al.
Publicado: (2019)

The Efficacy of Infliximab Monotherapy versus Infliximab-Azathioprine Sequential Treatment in Crohn's Disease: Experience from a Tertiary Medical Center in China
por: Zhang, Tianyu, et al.
Publicado: (2016)

Low Dose Infliximab for Prevention of Postoperative Recurrence of Crohn’s Disease: Long Term Follow-Up and Impact of Infliximab Trough Levels and Antibodies to Infliximab
por: Sorrentino, Dario, et al.
Publicado: (2015)

Serological Biomarkers of Intestinal Collagen Turnover Identify Early Response to Infliximab Therapy in Patients With Crohn’s Disease
por: Alexdottir, Marta S., et al.
Publicado: (2022)

Free antibodies-to-infliximab are biomarker for predicting the effect of dose intensification in pediatric Crohn’s disease patients with secondary loss of response
por: Kim, Eun Sil, et al.
Publicado: (2023)

How many biomarker measurements are needed to predict prognosis in Crohn's disease patients under infliximab?—A prospective study
por: Magro, Fernando, et al.
Publicado: (2023)

Infliximab-Induced Aseptic Meningitis in a Patient with Crohn’s Disease
por: Junga, Zachary, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_847kmok1o2bslq8hb0f5h6di13